Clinical and laboratory characteristics of lymphoproliferative diseases in primary Sjogren's syndrome associated with anticentromere antibodies

Purpose of the study. To study the characteristics and frequency of lymphomas in patients with Sjogren's disease (SD) and anticentromere antibodies (ACA); to evaluate the predictors of the development of lymphoproliferative diseases (LPD) in this group of patients. Material and methods. Over the period from 1998 till 2019, 131 ACA-positive patients were under medical supervision at the Research Institute of Rheumatology named after Nasonova V.A. Isolated SD was diagnosed in 82 patients (62.6%), isolated limited form of SSc — in 12 patients (9.2%), combination of SD and limited form of SSc — in 37 patients (28.2%). Lymphoproliferative diseases (LPD) were diagnosed in 20 ACA-positive patients: in 15 — with SD, in 5 — with SD and SSc; no lymphomas were found in the group of patients with isolated SSc. All lymphomas were diagnosed on the basis of histological, immunohistochemical and PCR examination with of B-cell clonality determination in the tissue, and were classified on the base of haematopoietic and lymphoid tissue tumors classification by the World Health Organization. Further analysis included 15 ACA-positive patients with isolated SD and lymphomas. Results. In our study, 18.3% of patients with isolated ACA-positive SD were diagnosed with LPD, represented by MALT lymphomas of the salivary glands (subsequent transformation into aggressive diffuse large B-cell lymphoma (DLBCL) was noted in one patient) in most cases. The course of SD before the diagnosis of LPD was characterized by a gradual progression of dental manifestations of SD with the development of late stages of parenchymal parotitis, severe xerostomia, and significant enlargement of the salivary glands with a minimum number of systemic manifestations of the disease. Significant enlargement of salivary glands, severe infiltration of minor salivary glands, severe xerostomia, decreased level of C4-complement component, monoclonal secretion, low content of CD19+B-cells in peripheral blood, positive B-cell clonality in biopsy material were the main signs of LPD in this study. When diagnosing MALT lymphomas, a focal damage of the salivary glands with no signs of dissemination, no symptoms of B-cell intoxication, and minimal changes in laboratory assessment were found in patients with ACA-positive SD. Conclusion. The natural course of ACA-positive SD and the absence of pathogenetic therapy at an early stage contribute to the development of salivary gland lymphomas in the first 10 years of the disease. Persistent enlargement of the salivary glands in SD, especially in the presence of other predictors of lymphoproliferation, is a direct indication for biopsy followed by the research to exclude the presence of lymphoma.

1. Talal N., Moutsopoulos H.M., Kassan (Editors). Sjogren’s Syndrome. Clinical and Immunological Aspects. Springer-Verlag. Berlin Heidelberg. 1987:1–299. DOI: 10.1007/978-3-642-50118-0

2. Fox R.I., Fox C.M. (Editors). Sjögren’s Syndrome: Practical Guide lines to Diagnosis and Therapy. Springer. 2011:1–506. DOI:10.1007/978-1-60327-957-4

3. Safonova T.N., Vasiliev V.I., Lihvanceva V.G. Sindrom SHyogrena: Rukovodstvo dlya vrachej [Sjögren's Syndrome: A Guide for Physicians]. Moscow State University Publishing House; 2013:1–599. (in Russian)]. ISBN 978-5-19-010836-1

4. Chaltsev B.D., Vasilyev V.I., Palshina S.G., Torgashina A.V., Sokol E.V., Khvan Yu.I., Safonova T.N., Rodionova E.V., Gaiduk I.V., Borozdkin L.L. Clinical and laboratory features of anticentromere antibody-positive sjögren’s syndrome. Rheumatology Science and Practice. 2019;57(4):431–439. (in Russian)]. DOI:0.14412/1995-4484-2019-431-439

5. Notarstefano C., Croia C., Pontarini E. et al. A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjögren's syndrome. Clin. Exp. Rheumatol. 2018;36 Suppl 112(3):145–149.

6. Baldini C., Mosca M., Della Rossa A. et al. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin. Exp. Rheumatol. 2013;31(2):272–280.

7. LeRoy E.C., Medsger T.A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 2001;28(7):1573–1576.

8. van den Hoogen F., Khanna D., Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2013;72(11):1747–1755. DOI: 10.1136/annrheumdis-2013-204424

9. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Editors. Swerdlow S.H., Campo E., Harris N.L., Jaffe T.S., Pieri S.A., Stein H., Thiele J. (Revised 4th edition). IARC: Lyon, 2017, 1–523.

10. Vasil'ev V.I., Chal'tsev B.D., Gorodetskii V.R. et al. The relationship between Sjogren’s syndrome, systemic sclerosis and lymphoproliferative diseases. Terapevticheskii arkhiv. 2020;92(12):126–136. (In Russian)]. DOI: 10.26442/00403660.2020.12.200443

11. Vasil'ev V.I., Logvinenko O.A., Probatova N.A. et al. The role of parotid gland biopsy in early detection of lymphoma in primary Sjogren's syndrome. Terapevticheskii arkhiv. 2009;81(6):20–26. (in Russian)]

12. Vasilyev V.I., Gai duk I.V., Palshina S.G., Gorodetsky V.R., Sokol E.V., Rodio nova E.B., Burtseva M.V., Shornikova N.S., Probatova N.A., Kokosadze N.V., Pavlovskaya A.I., Kupryshina N.A., Safonova T.N. Primary hematologic malignancies with the onset of involvement of the major salivary glands in rheumatologic practice. Modern Rheumatology Journal. 2019;13(1):44–51. (in Russian)]. DOI:10.14412/1996-7012-2019-1-44-51

13. Tsukamoto M., Suzuki K., Seta N., Takeuchi T. Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study [abstract]. Arthritis Rheumatol. 2017;69(10).

14. Suzuki Y., Fujii H., Nomura H. et al. Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: a retrospective cohort study. Mod. Rheumatol. 2018;28(5):872–878. DOI:10.1080/14397595.2017.1418164

15. Avouac J., Sordet C., Depinay C. et al. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheumatol. 2006;54(7):2243–2249. DOI: 10.1002/art.21922

16. Horimoto A.M.C., de Macedo Possamai V., da Costa I.P. Sjögren’s Syndrome and Sicca Symptoms in Patients with Systemic Sclerosis. J. Arthritis. 2016;5:190. DOI: 10.4172/2167-7921.1000190

17. Васильев В.И. Болезнь Шегрена: клинико-лабораторные, иммуноморфологические проявления и прогноз. Авт. дис. д-ра мед. наук. Москва, 2007:1–46. [Vasil'ev V.I. Primary Sjogren’s syndrome:cli nical, laboratory and immunomorphological manifestations and pro gnosis. Avt. dis. dokt. med. nauk. Moskva, 2007:1–46. (in Russian)]

18. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002;46(3):741–747. DOI: 10.1002/art.10221

19. Routsias J.G., Goules J.D., Charalampakis G., Tzima S., Papageor giou A., Voulgarelis M. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin. Arthritis Rheum. 2013;43(2):178–186. DOI: 10.1016/j.semarthrit.2013.04.004

20. Vivino F.B., Bunya V.Y., Massaro-Giordano G. et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin. Immunol. 2019;203:81–121. DOI: 10.1016/j.clim.2019.04.009

21. Goules A.V., Tzioufas A.G. Lymphomagenesis in Sjögren's syndrome: Predictive biomarkers towards precision medicine. Autoimmun. Rev. 2019;18(2):137–143. DOI: 10.1016/j.autrev.2018.08.007

22. Kapsogeorgou E.K., Voulgarelis M., Tzioufas A.G. Predictive markers of lymphomagenesis in Sjögren's syndrome: From clinical data to molecular stratification. J. Autoimmun. 2019;104:102316. DOI: 10.1016/j.jaut.2019.102316

23. Ekström Smedby K., Vajdic C.M., Falster M. et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–4038. DOI: 10.1182/blood-2007-10-119974

24. Vasiliev V.I., Probatova N.A., Tupicyn N.N. et al. Lymphoproliferative Diseases in Sjogren’s Syndrome. Onkogematologia = Oncohematology. 2007;3:16–26. (in Russian)]

25. Gorodetskiy V.R., Klapper W., Probatova N.A., Vasilyev V.I., Rozhnova E.V. Simultaneous Occurrence of Rosai-Dorfman Disease and Nodal Marginal Zone Lymphoma in a Patient with Sjögren's Syndrome. Case Rep. Hematol. 2018;2018:7930823. Published 2018 Sep 16. DOI: 10.1155/2018/7930823

26. Vasil'ev V.I. et al. The first experience of using rituximab in the treatment of patients with primary and secondary Sjogren's syndrome. Vestnik Rossijskoj AMN. 2009;2:3–10. (in Russian)]

27. Jordan R.C., Odell E.W., Speight P.M. B-cell monoclonality in salivary lymphoepithelial lesions. Eur. J. Cancer B. Oral. Oncol. 1996;32B(1):38–44. DOI:10.1016/0964-1955(95)00050-x

28. Harris N.L. Lymphoid proliferations of the salivary glands. Am. J. Clin. Pathol. 1999;111(1 Suppl 1):S94–S103.